H.C. Wainwright analyst Ed Arce maintained a Hold rating on Avenue Therapeutics (ATXI) today. The company’s shares closed last Monday at $3.02, close to its 52-week low of $2.22.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 20.5% and a 46.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Avenue Therapeutics with a $12.00 average price target.
See today’s analyst top recommended stocks >>
Avenue Therapeutics’ market cap is currently $50.58M and has a P/E ratio of -14.50. The company has a Price to Book ratio of 47.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.
